

CENTENE PHARMACY THERAPEUTICS COMMITTEE  
POLICY AND PROCEDURE SUMMARY TABLE  
1Q2018 HEALTH INSURANCE MARKETPLACE

Coverage Criteria Guideline	Status	Revision Summary Description
HIM.PHAR.01 Pharmacy Grievance	No Significant Change	Policy reviewed. No changes.
HIM.PHAR.02 Pharmacy Appeals	No Significant Change	Added Note: Nothing in this policy should be construed to imply that Envolve Pharmacy Solutions will process appeals on behalf of the plans.
HIM.PHAR.03 Pharmacy and Therapeutics Committee	No Significant Change	Policy reviewed. No changes.
HIM.PHAR.04 Drug Utilization Review	No Significant Change	Policy reviewed. No changes.
HIM.PHAR.05 Lost or Stolen Medications	No Significant Change	Policy reviewed. No changes.
HIM.PHAR.06 PBM Inquiry for Additional Information	No Significant Change	Policy reviewed. No changes.
HIM.PHAR.16 Vacation Overrides	No Significant Change	Policy reviewed. No changes
HIM.PHAR.11 Requests for Pharmacy Profiles	Significant Changes	Under Policy section inserted “clinical” after insufficient and before information. Inserted “review the request based on presented information. If the reviewer is unable to approve the request, the PA...” after Envolve Pharmacy Solutions reviewer will. Removed: “fax a response (Attachment A: Response to Prior Authorization medication Request decision. The PA”. Removed: “for purposes of reporting after “unable to approve”. Inserted: “If the request is incomplete or is missing non-clinical information such as provider signature Envolve Pharmacy Solutions reviewer will fax informational fax to provider stating which section of the PA form is missing.” Removed section: “If the information requested is not submitted by the prescriber within 48 hours, the request is considered and adverse benefit determination (denial) and no further action is taken” from the end of the paragraph. Added “For Reviews with insufficient clinical information” title under Procedure. Added section: For reviews with insufficient non-clinical information:” Under procedure replaced reference to 24 hour turn around time to “within appropriate turn around time”. Turn around time varies from state to state and type of request.
HIM.PHAR.13 Drug Recall Notification	Significant Changes	Changed section #3. Letter templates will be sent from Envolve to local Marketing Department. Changed section #5 and added: “Once local Marketing Department provides versioned and approved member and provider letters,” Changed responsibility

CENTENE PHARMACY THERAPEUTICS COMMITTEE  
POLICY AND PROCEDURE SUMMARY TABLE  
1Q2018 HEALTH INSURANCE MARKETPLACE

		of letter mailing from Ambetter Director of Pharmacy to Health Plan Director of Pharmacy to allow for better operationalization of recalls.
HIM.PHAR.18 Pharmacy Lock-In Program	Significant Changes	Under Procedure removed: Prescribed medications do not correlate with Member’s medical condition, as identified by his/her PCP or ICD-10 code from encounter data as this section is very broad and doesn’t appear to be specific to narcotics. Changed section requiring fills at three or more pharmacies to omit requirement that the fills have to have taken place “over last 30 consecutive days within the previous 12 months” as it is not very clear. Section now only requires three or more pharmacies. Clarified that prescribers located in the same office at the same physical address do not count as multiple providers. Changed ER visit requirement from seven to four to account for Lock-In criteria presented in the table. Added alcohol/drug abuse to section of narcotic poisoning/suicidal attempt. Removed section on “Prescriptions written on a stolen, forged or altered prescription blank” as there would be no way to prove or confirm occurrence of such event. Removed “Drugs of high abuse potential such as Holy Trinity or Houston Cocktail, opioids or benzos in combination” since we have no reliable way of obtaining information on abuse of “street” drugs and combination of benzodiazepines and opioids is addressed in HIM.PA.149. Removed sections that member is eligible for Lock-In if member is either undergoing group counseling for substance abuse or is under supervision of pain management specialist as this would indicate attempt at stopping addiction or close follow up. Under criteria revised sections to correspond to Procedure. Added clarifications that members can be sent to CM or sent to CM and Locked-in for members in 5-8 points bracket. Changed section #5 to reflect the Lock-in timeframe of 7-10 post identification This was changed from 10 days. Revised section #7 to allow for vacation exception only in special cases. Under Exclusion criteria changed section to state that special considerations will be given to people that have either malignant neoplasm or Sickle Cell Disease. The section does no longer offer automatic exclusion.
HIM.PHAR.14 Approval of Brand-Name Override	Retired	Policy retired. Subject addressed with guideline HIM.PA.103.